July 17, 2018 / 5:14 AM / 9 months ago

Roche nabs trial win for investigational anti-viral flu drug

ZURICH, July 17 (Reuters) - Roche said on Tuesday its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications from flu, a boost to the Swiss drugmaker’s efforts to win approval for the single-dose, oral anti-viral medicine.

Sandra Horning, Roche’s chief medical officer, said the drug showed a clinical meaningful benefit in older people and those with medical conditions. The company plans to submit the results of the study, called Capstone-2, to regulators, she said.

Reporting by John Miller; Editing by Stephen Coates

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below